Imaging Biometrics of Milwaukee has signed an agreement with the American College of Radiology Imaging Network (ACRIN) to evaluate MRI datasets using its IB Neuro dynamic susceptibility contrast (DSC) MR perfusion software.
ACRIN (#6677) is a global multicenter phase II trial using advanced imaging to track the effectiveness of biological treatments for brain tumors.
IB Neuro uses DSC algorithms to provide information about blood volume and blood flow in the brain. The perfusion parameters are helpful in the detection of new tumor growth or tumor recurrence and are designed to assist in creating personalized treatment plans for patients.
Related Reading
FDA clears MR perfusion package, June 6, 2008
Copyright © 2008 AuntMinnie.com
